Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Other Operating Expenses (2016 - 2026)

Ani Pharmaceuticals' Other Operating Expenses history spans 16 years, with the latest figure at -$87000.0 for Q4 2025.

  • On a quarterly basis, Other Operating Expenses changed N/A to -$87000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $182.6 million, a 39.05% increase, with the full-year FY2025 number at -$382000.0, down 107.14% from a year prior.
  • Other Operating Expenses hit -$87000.0 in Q4 2025 for Ani Pharmaceuticals, up from -$295000.0 in the prior quarter.
  • Over the last five years, Other Operating Expenses for ANIP hit a ceiling of $99.2 million in Q2 2025 and a floor of -$8.4 million in Q2 2021.
  • Historically, Other Operating Expenses has averaged $45.1 million across 5 years, with a median of $53.4 million in 2023.
  • Biggest five-year swings in Other Operating Expenses: crashed 124.47% in 2021 and later soared 672.32% in 2022.
  • Tracing ANIP's Other Operating Expenses over 5 years: stood at -$350000.0 in 2021, then skyrocketed by 13835.71% to $48.1 million in 2022, then surged by 46.85% to $70.6 million in 2023, then grew by 3.05% to $72.8 million in 2024, then crashed by 100.12% to -$87000.0 in 2025.
  • Business Quant data shows Other Operating Expenses for ANIP at -$87000.0 in Q4 2025, -$295000.0 in Q3 2025, and $99.2 million in Q2 2025.